Company intelligence / Profile preview

ABBA Therapeutics

Basel, Switzerland

Ownership: Private
Development stage: Other

Overview

ABBA Therapeutics has multiple programs in preclinical development focusing on cancer immunotherapy, including ABBA-19 for sarcoma and solid tumors, with one discontinued cancer therapeutics program

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyBispecific antibodyBispecific monoclonal antibody
Industry: Biotech

Partnerships

Ligand Pharmaceuticals

Beyond the preview

Go deeper on ABBA Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABBA Therapeutics.

Explore the full profile